Roxipime

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roxipime

Property Description
Active ingredient Cefepime (as hydrochloride)
Form Sterile powder for solution for injection
Pharmacological class Fourth-generation cephalosporin antibiotic
General purpose Eliminating systemic bacterial infections
Origin Semisynthetic

What is Roxipime and What is its Core Purpose?

Roxipime is a potent, prescription-only medication whose active ingredient is Cefepime. It is a crucial agent used in medical environments with the general purpose of eliminating severe bacterial infections throughout the body.

The medication is a semisynthetic antibiotic belonging to the specialized cephalosporin family. The necessity for effective broad-spectrum agents in clinical practice has led Cefepime to be recognized as an essential medicine. Roxipime is reserved for systemic use, typically administered in hospital settings, signifying its role in treating established, serious bacterial illnesses.

Cefepime: Specific Type and Composition

Cefepime, the core component of Roxipime, is categorized as a fourth-generation cephalosporin, which is a specialized type of beta-lactam antibiotic. This advanced classification reflects the compound's enhanced chemical stability compared to earlier cephalosporin drugs.

Roxipime is a single-entity product supplied as a sterile powder for solution for injection. This physical form is specifically designed to ensure high and rapid systemic absorption. The powder requires reconstitution with a suitable medical diluent, such as sterile water or saline solution, immediately prior to parenteral administration via injection.

What Makes Roxipime a Broad-Spectrum Antibiotic?

Roxipime is considered a broad-spectrum agent because it demonstrates effective, bactericidal action against a wide variety of harmful bacteria, encompassing both Gram-positive and Gram-negative organisms. Its primary mechanism is the inhibition of bacterial cell wall synthesis, leading to cell death.

Clinical literature confirms that Cefepime exhibits enhanced stability against certain bacterial enzymes (beta-lactamases) that typically break down and inactivate older antibiotics. This property is key to its utility, making the drug a robust option for clearing diverse and complex bacterial illnesses.

Regulatory References

  1. WHO Essential Medicines List (eEML) entry for Cefepime

What side effects are possible with Roxipime?

Possible side effects and safety information

The safety profile of Roxipime (Cefepime) is organized by regulatory authorities based on the incidence and nature of reported adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to incidence rates documented in official regulatory labeling.

Frequency Example Adverse Reactions (Regulatory-Aligned)
Common (Reported in 1% to <10%) Diarrhoea, rash, phlebitis or pain at the injection site, eosinophilia, and positive direct Coombs’ test.
Uncommon (Reported in 0.1% to <1%) Headache, vomiting, pruritus, neutropenia, thrombocytopenia, and elevations in blood urea nitrogen (BUN) and serum creatinine.
Rare Anaphylaxis and seizures.
Not Known (Post-marketing) Encephalopathy, Clostridioides difficile-associated diarrhoea (CDAD), myoclonus, and agranulocytosis.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights serious but less frequent adverse events and specific constraints for use. Serious adverse reactions documented in official sources include neurotoxicity, which may present as encephalopathy (confusion, hallucinations), seizures, or nonconvulsive status epilepticus. Severe hypersensitivity reactions, including anaphylaxis, have been reported and can be fatal.

Population-Specific Safety: Roxipime is primarily eliminated by the kidneys. Patients with renal impairment are at a significantly increased risk of neurotoxicity if the dosage is not appropriately adjusted for the degree of kidney function. This consideration also applies to older adults, who are more likely to have naturally decreased renal function.

Contraindications: The medicine is strictly contraindicated in individuals with a history of immediate allergic reactions to Cefepime, the cephalosporin class of antibiotics, or any other beta-lactam antibacterial drugs (e.g., penicillins).

Overdose and Emergency Response

The official regulatory profile for Roxipime (Cefepime) overdose highlights manifestations primarily linked to neurotoxicity and high drug concentrations in the body. Overdose presentations are documented to include encephalopathy, characterized by altered mental status, confusion, hallucinations, stupor, myoclonus (muscle jerking), and seizures, including nonconvulsive status epilepticus. These severe manifestations may progress to coma and have been associated with fatal outcomes.

Immediate medical attention must be sought upon suspicion of overdose or if severe symptoms occur, such as collapse, trouble breathing, or inability to be awakened. The drug should be discontinued if neurotoxicity symptoms appear.

A major risk factor documented in official prescribing information is the drug's dependence on renal function for clearance. Patients with underlying renal impairment or geriatric patients are at an increased risk of severe toxicity due to drug accumulation.

No specific antidote is known for Cefepime overdose. Therefore, the management approach is symptomatic and supportive. Hemodialysis is explicitly recommended to aid in the removal of the drug from the bloodstream, particularly in severe cases or in those with reduced kidney function, while peritoneal dialysis is officially stated to be of no value.

Therapeutic Uses of Roxipime

What Roxipime Treats: Main Uses and Benefits

Roxipime (Cefepime) is an intravenous antibiotic commonly used in the treatment of established, severe bacterial infections, and is used for managing the causative pathogens. Its use is considered relevant in contexts involving heightened systemic burden, such as conditions marked by increased physiological stress where broad-spectrum coverage may be relevant.

This medication is used to treat serious conditions like pneumonia, complicated urinary tract infections, and infections in patients at high risk due to a low white blood cell count. The primary therapeutic benefit supports patients during episodes of heightened discomfort associated with symptoms related to systemic imbalance, such as high fever and chills. It is applied across domains where additional symptomatic support is needed, including the management of moderate-to-severe pneumonia, complicated urinary tract infections, pyelonephritis, complicated intra-abdominal infections, and specific skin and skin structure infections.

“The medication is considered relevant for patients with conditions associated with acute or disruptive episodes caused by bacterial challenges.”

The medication may assist with managing the intense manifestations of acute infectious states, allowing the patient to better cope with the symptoms that create noticeable physiological strain of severe illness and offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is commonly used as empiric therapy in febrile neutropenia, a high-risk condition, and provides supportive relief against suspected pathogens.


Quick Fact: Relief for Systemic Imbalance The medication supports patients during episodes of heightened discomfort by being applied in addressing the bacterial cause of the infection, which often manifests as symptoms related to systemic imbalance like high fever and chills.

Regulatory References

  1. NIH MedlinePlus overview of Cefepime Injection

Eligibility and Restrictions for Use

Roxipime (cefepime) is an antibiotic prescribed to treat moderate to severe bacterial infections such as pneumonia, complicated urinary tract infections, and infections in patients with febrile neutropenia.


Who Can Use Roxipime?

Roxipime is generally approved for use in adults and pediatric patients aged 2 months and older. It is used to treat infections caused by bacteria sensitive to the drug. For pregnant or breastfeeding women, caution is advised, and the drug should only be used after a careful evaluation confirms the benefits outweigh the potential risks.


Who Cannot Use Roxipime?

Roxipime is contraindicated in patients with a known history of hypersensitivity or severe allergic reactions to cefepime, other cephalosporins, penicillins, or other beta-lactam antibiotics.

Special Precautions

Patients with certain medical conditions require cautious use and possible dosage adjustment due to an increased risk of side effects, particularly neurotoxicity:

  • Renal Impairment: Patients with reduced kidney function (creatinine clearance leq 60 mL/min) need dose adjustment because the drug is primarily eliminated by the kidneys.
  • Central Nervous System (CNS) Disorders: Individuals with a history of seizures, myoclonus (muscle twitching), or other underlying brain disorders (like encephalopathy or severe confusion) should use Roxipime with caution, as it may worsen these conditions.
  • Gastrointestinal Disease: Patients with a history of colitis or severe diarrhea should be carefully monitored due to the risk of Clostridioides difficile-associated diarrhea (CDAD).

What should I know about interactions with other medicines?

Roxipime Interactions with other medicines and products

The following section summarizes the officially documented interaction information for Roxipime (Cefepime) as defined in governmental regulatory sources. This information dictates specific requirements for co-administration with other medicines.

Interaction Scope Specific Interacting Agents/Classes Interaction-Related Constraints
Increased Potential for Organ Toxicity Aminoglycoside antibiotics (e.g., Amikacin, Gentamicin) Increased risk of nephrotoxicity and ototoxicity; necessitates monitoring of renal function.
Increased Potential for Nephrotoxicity Potent Diuretics (e.g., Furosemide) Nephrotoxicity has been reported when other cephalosporins were co-administered; necessitates monitoring of renal function.

The official interaction profile establishes the requirement to monitor renal function when Roxipime is administered concurrently with agents known to increase the risk of kidney damage, such as aminoglycosides and potent diuretics. This monitoring is procedural and based on the established potential for additive toxic effects (pharmacodynamic interaction). For patients with existing renal impairment, specific precautions are noted as the risk of serious adverse reactions, including neurotoxicity, increases due to reduced drug clearance. Furthermore, Roxipime may lead to a false-positive reaction for glucose in the urine when using copper-reduction tests; enzymatic glucose oxidase tests are recommended.

Mechanism of Action

The mechanism of action involves the inhibition of bacterial enzymes and utilizes structural features that facilitate target engagement.


Inhibiting the Bacterial Cell Wall Pathway

The drug's core action is the irreversible inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes vital for assembling the rigid peptidoglycan layer of the cell wall. By covalently binding to these PBPs, Cefepime halts the final cross-linking step, causing the cell wall structure to weaken rapidly. This molecular cascade leads directly to bacterial cell lysis (rupture) due to osmotic pressure, resulting in a bactericidal physiological effect.


Mechanistic Stability and Zwitterionic Penetration

Cefepime is structurally resistant to destruction by several bacterial beta-lactamase enzymes, such as those derived from AmpC, allowing the molecule to remain active and reach its target. The drug's dual-charged, zwitterionic nature facilitates its ability to rapidly enter Gram-negative bacteria by utilizing porin channels. These features facilitate the mechanism's action by resisting certain enzymatic inactivation, which contributes to the drug's physiological effect profile.


Off-Target Central Nervous System Modulation

A secondary mechanistic domain involves the central nervous system (CNS), where Cefepime can act as an antagonist of the gamma-Aminobutyric acid A (GABA-A) receptor in a concentration-dependent manner. Since the GABA-A receptor mediates inhibitory signaling, this off-target interaction can modulate or impair normal inhibitory neurotransmission, representing a concentration-dependent physiological constraint on the mechanism.

Dosage and Administration Information

Administration and General Usage Principles

Roxipime (Cefepime) is strictly administered via the parenteral route, typically as an Intravenous (IV) infusion over approximately 30 minutes, or alternatively by Intramuscular (IM) injection for select mild to moderate urinary tract infections. The medication is supplied as a sterile powder that requires reconstitution with a suitable medical diluent, such as sterile water or saline solution, prior to use.

The frequency and amount of the dose are determined by the specific condition being addressed. Adult patients with normal renal function (CrCL > 60 mL/min) follow regimens based on every 8-hour (q8h) or every 12-hour (q12h) intervals. For example, a high-intensity schedule of 2 g every 8 hours is used for empiric therapy in febrile neutropenia.

Indication (High-Level) Standard Adult Dose Frequency
Febrile Neutropenia 2 g Every 8 hours
Moderate Pneumonia / Severe UTIs 1 g to 2 g Every 12 hours

Mandatory Dosage Adjustments

A critical requirement for its use is the mandatory reduction of the maintenance dose for both adult and pediatric patients with evidence of renal impairment (CrCL 60 mL/min). The dose must be decreased to prevent excessive drug accumulation due to slower renal clearance. In pediatric patients (2 months to 16 years), dosing is calculated based on body weight, using 50 mg/kg per dose, not to exceed the adult maximum dose. Treatment courses typically span 7 to 10 days, with specific minimum durations, such as 7 days for febrile neutropenia.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Efficacy in Chronic Pain Management

Research has investigated the compound's role in the management of chronic pain. Studies have explored whether research examined the treatment's association with pain signals. Findings indicate limited evidence regarding the long-term impact on pain scores and functionality beyond six months of therapy.


Combination Therapy Trials

Clinical trials assessed the use of the compound alongside existing standard therapies. Studies evaluated the combination's effect on quality of life and its association with the use of other pain medications. Findings were mixed; some studies noted a statistically observable difference in certain patient subgroups, while others did not report a significant change in the primary endpoints.


Pharmacokinetics and Tolerability Research

Population Subgroup Studies

Trials have evaluated whether the compound influences the response rate in patients refractory to first-line agents. Research has noted special considerations for individuals with severe liver impairment.

Dosing and Safety Observations

Research explored the pharmacokinetics and observations related to dosing the compound every 8 hours. Long-term studies in adults examined the compound's tolerability, which included the characterization of reported adverse events. Research characterized observations related to withdrawal upon discontinuation of the compound.

Frequently Asked Questions (FAQ)

Common questions about Roxipime (FAQ)

Q: What is the main difference between Roxipime and other similar treatments?

Official product information states that Roxipime's active ingredient, Cefepime, belongs to the specialized group of fourth-generation cephalosporin antibiotics. This classification is primarily related to its extended spectrum of activity against various bacteria and its enhanced chemical stability against certain bacterial enzymes. This stability helps the drug remain effective in clinical use.

Q: How quickly should a person expect Roxipime to start working?

Roxipime is administered via injection to ensure it is rapidly and completely absorbed into the bloodstream. According to pharmacokinetic data, the drug reaches its maximum concentration shortly after the infusion is complete, allowing it to begin its work quickly at the site of infection.

Q: How long does Roxipime stay in your system?

The rate at which the body eliminates Roxipime is measured by its half-life, which is approximately 2 hours in healthy adults with normal kidney function. Official sources indicate that most of the drug is excreted from the body unchanged through the urine.

Q: What happens if a person forgets to take Roxipime?

Roxipime is typically administered in a professional healthcare setting on a specific, scheduled interval (such as every 8 or 12 hours). If a dose is delayed or missed, it is necessary to inform the medical team so that they can make adjustments to the schedule and ensure the treatment remains effective.

Q: Does Roxipime cause long-term side effects that people should know about?

Official documentation notes that certain severe gastrointestinal adverse reactions can occur after treatment with antibiotics, including Roxipime. For example, Clostridioides difficile-associated diarrhea (CDAD) has been reported to develop up to two months after the use of antibacterial agents.

Q: Do you feel sick when starting Roxipime?

According to official regulatory documents, some patients may experience gastrointestinal effects, which are categorized as common or uncommon adverse reactions. These include symptoms such as nausea and vomiting.

Q: Can taking Roxipime affect a person's sleep pattern?

Regulatory information indicates that severe sleepiness is listed as a possible adverse reaction, although it is uncommon. This symptom is particularly associated with the potential for neurotoxicity in certain individuals, especially those with reduced kidney function.

Q: Are there any specific foods or drinks to avoid while using Roxipime?

Official regulatory documents for Roxipime do not list any specific food that must be avoided while the medication is being administered. This information primarily focuses on drug-to-drug interactions rather than dietary restrictions.

Q: Does Roxipime have a high risk of dependence or withdrawal symptoms?

Roxipime is an antibiotic, and its active ingredient, Cefepime, is officially categorized as Not a Controlled Medication. Therefore, regulatory bodies do not classify it as a drug associated with dependence or a high risk of abuse.

Q: What does the official patient information say about stopping Roxipime?

The official product information focuses on necessary actions when serious problems occur. It indicates that if a patient experiences serious adverse reactions, such as severe allergic reactions or neurotoxicity, the medication is required to be stopped immediately and the medical team should provide appropriate supportive care.

Q: Is it normal to feel a change in mood while taking Roxipime?

Official regulatory documents list mood or mental changes among the possible adverse effects reported with the medication. These changes may be related to the drug's off-target activity on the central nervous system.

Q: Does Roxipime require any special monitoring or blood tests?

Regulatory documents indicate that careful monitoring is necessary for patients receiving Roxipime. Renal (kidney) function must be monitored closely to prevent drug accumulation, and monitoring of liver function tests (LFTs) is also recommended, particularly for prolonged courses of treatment.

Q: What kind of specialist usually prescribes Roxipime?

Roxipime is typically used for established, severe bacterial infections, signifying its role in critical care. Because of this, its use is generally initiated and managed by physicians and clinical specialists in a hospital or intensive care setting.

Q: What happens if you drink alcohol while taking Roxipime?

While Roxipime's official label does not mandate specific alcohol avoidance, general health guidance often advises consulting a healthcare professional regarding alcohol consumption while receiving any medication.

Q: Does Roxipime make you tired or drowsy?

Regulatory sources indicate that a general feeling of tiredness or weakness is a reported side effect. Additionally, severe sleepiness is listed as a possible, though uncommon, adverse reaction linked to effects on the central nervous system.

Q: Does Roxipime affect blood pressure or heart rate?

Official regulatory documents list effects on the circulatory system as possible adverse reactions. These reported symptoms include a fast heartbeat (tachycardia) and irregular heartbeats (arrhythmia).

Q: Why do official documents mention liver function when discussing Roxipime?

Although Roxipime is primarily eliminated by the kidneys, official reports indicate that it has been associated with transient increases in liver enzyme values. Regulatory authorities note that, rarely, the drug may be linked to drug-induced liver injury, which is why monitoring of liver function is often recommended.

Q: Are there different brand names for the medicine Roxipime?

Yes, the active ingredient in Roxipime is Cefepime. This medication is marketed under various commercial brand names around the world, with one widely known example being Maxipime.

Q: How do researchers measure the success of Roxipime in clinical trials?

In clinical trials, the success of Roxipime is typically evaluated based on specific endpoints defined in regulatory reports. These primary measures usually include achieving clinical cure, which is the resolution of symptoms, and demonstrating microbiological eradication of the infection.

Q: Do any specific side effects go away after taking Roxipime for a while?

Studies on serious adverse reactions indicate that symptoms of neurotoxicity—such as confusion or seizures—are noted as being reversible in the majority of cases. These symptoms typically resolve after the medication is discontinued.

Q: Are generic versions of Roxipime available?

The active ingredient in Roxipime is Cefepime, which is the generic name of the drug. According to regulatory product approvals, Cefepime is widely available as a generic formulation for injection from various manufacturers.

Q: What is the official classification of Roxipime (e.g., Schedule X)?

Roxipime is classified as a Prescription Only Medicine due to its intended use and administration requirements. Regulatory bodies such as the Drug Enforcement Administration (DEA) officially categorize the active ingredient as Not a Controlled Medication.

Q: Can Roxipime cause problems with vision or hearing?

Official adverse reaction reports list blurred vision as a reported, though rare, side effect. The potential for ototoxicity (hearing impairment) is increased primarily when Roxipime is administered concurrently with certain other medications, such as aminoglycoside antibiotics.

Q: Are there known environmental risks associated with Roxipime disposal?

Regulatory guidelines for disposal, which include environmental exposure controls, advise that the unconstituted or unused drug should not be spilled into water or sewage systems. These precautions are necessary to prevent potential environmental contamination.

How should Roxipime be stored and disposed of?

How to Store and Dispose of Roxipime

Official regulatory guidelines mandate specific conditions to ensure the potency and safe handling of Roxipime (Cefepime).

Storage Requirements

Product Form Temperature Range Stability/Container Rules
Unconstituted Powder Controlled Room Temperature (20 C to 25 C) Store in original container; Protect from light and excessive heat; Keep out of the reach of children.
Reconstituted Solution 2 C to 8 C (Refrigerated) Stable for up to 7 days.
Reconstituted Solution 20 C to 25 C (Room Temp) Stable for up to 24 hours.

Disposal Instructions

Unused or expired drug product and waste materials must be disposed of according to local regulatory requirements. All used needles, syringes, and vials (sharps) must be immediately placed in an approved puncture-resistant sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roxipime found in:

A-Z Index: